# Freedom Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/freedom-biosciences

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.freedombio.co
- Total disclosed funding: $11M
- Latest round: Seed (Aug 23, 2022)
- Investors on record: 4

## About

Based in California, US, and founded in 2021, Freedom Biosciences operates as a biotech company. The company was founded by its CEO Dina Burkitbayeva, CSO John Krystal, Hunter Bouchard, and Morgan Springer. In August 2022, Freedom Biosciences raised USD 10.5 million in seed funding led by MBX Capital, PsyMed Ventures, The Yale Startup, and Village Global.

Freedom Biosciences develops and offers FREE001, which is a ketamine treatment that is used for the treatment of major depressive illness. The company offers various ketamine and psychedelic-based treatments to patients suffering from mental health disorders.

The company plans to use the funds raised in August 2022 to advance its present lead ketamine program and an additional number of extra exploratory packages.

## Funding rounds

- Seed, Aug 23, 2022, $11M — Village Global, MBX Capital, PsyMed Ventures, The Yale Startup

## Investors

- Village Global (https://capitalatlas.ai/funds/village-global) — Seed
- MBX Capital (https://capitalatlas.ai/funds/mbx-capital) — Seed
- PsyMed Ventures (https://capitalatlas.ai/funds/psymed-ventures) — Seed
- The Yale Startup — Seed